Get started
Author

Momoko Oe

Observed names: MOMOKO OE, Oe, Momoko
Observed institutions: Kowa (Japan), Niigata University
ORCID: 0009-0005-5152-3762
Observed ORCID: 0009-0005-5152-3762
OpenAlex ID: A5018490489
Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese
2021 · Momoko Oe, Kazuya Fujihara, et al. · Cardiovascular Diabetology · 10
PDF
Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
2021 · Yasuhiro Matsubayashi, Akihiro Yoshida, et al. · Diabetes Obesity and Metabolism · 8
Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium‐glucose cotransporter‐2 inhibitor tofogliflozin
2022 · Yasuhiro Matsubayashi, Alkihiro Yoshida, et al. · Diabetes Obesity and Metabolism · 6
PDF
Risk stratification for cardiovascular disease based on prior coronary artery disease, cerebrovascular disease and type 2 diabetes mellitus
2024 · Momoko Oe, Kazuya Fujihara, et al. · Journal of Diabetes Investigation · 2
PDF
Impact of Prior Cerebrovascular Disease and Glucose Status on Incident Cerebrovascular Disease in Japanese
2021 · Momoko Oe, Kazuya Fujihara, et al. · Research Square · 1
PDF
The Relationship Between Triglycerides and Coronary Artery Disease Stratified by Sex and High‐Density Lipoprotein Cholesterol in Men and Women
2026 · Momoko Oe, Kazuya Fujihara, et al. · Diabetes/Metabolism Research and Reviews
1286-P: Impact of Changes in Glucose Tolerance Status on Incidence of Cardiovascular Disease in Japan—Historical Cohort Study Using a Nationwide Claims Database
2024 · CHIHIRO SHIMAYAMA, KAZUYA FUJIHARA, et al. · Diabetes
脳血管疾患の既往および耐糖能とその組み合わせがその後の脳血管疾患発症に与える影響
2023 · Oe, Momoko · Institutional Repositories DataBase (IRDB)
Author response for "Predictors of hemoglobin and its changes focusing on anemia and polycythemia after administration of the SGLT2 inhibitor, tofogliflozin"
2022 · Yasuhiro Matsubayashi, Akihiro Yoshida, et al. · Publons reviews and discussion
325-OR: Associations of Systolic Blood Pressure (SBP) with the Incidence of Heart Failure (HF) According to Glucose Tolerance Status (GTS)
2022 · KAZUYA FUJIHARA, MAYUKO H. YAMADA, et al. · Diabetes
991-P: Association between Glucose Abnormality Status and Previous Cerebrovascular Disease (CVD) on Subsequent CVD in Japanese Men Using Real-World Data
2021 · MOMOKO OE, KAZUYA FUJIHARA, et al. · Diabetes
Author response for "Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the SGLT2 inhibitor, tofogliflozin"
2021 · Yasuhiro Matsubayashi, Akihiro Yoshida, et al. · Publons reviews and discussion
Author response for "Association of estimated plasma volume and weight loss after long‐term administration and subsequent discontinuation of the SGLT2 inhibitor, tofogliflozin"
2021 · Yasuhiro Matsubayashi, Akihiro Yoshida, et al. · Publons reviews and discussion
1133-P: Association of Higher Baseline BNP Levels with a Greater Reduction in Plasma Volume and Increase in Beta-Hydroxybutyrate via the SGLT2 Inhibitor Tofogliflozin in Type 2 Diabetes
2020 · AKIHIRO YOSHIDA, YASUHIRO MATSUBAYASHI, et al. · Diabetes
Works count: 14
Citation count: 27
H-index: 3
I10-index: 1
Year
Topic
Type